This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TG Therapeutics, Inc. Initiates A Phase I/II Clinical Trial Of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, Ublituximab, In Patients With Relapsed Or Refractory B-cell Non-Hodgkin's Lymphoma

Stock quotes in this article: TGTX

Multi-Center Phase I/II Trial Led by Dr. Owen O'Connor, MD, PhD, Director, Center for Lymphoid Malignancies, New York Presbyterian Columbia Medical Center

TG Therapeutics to Host a Conference Call on Thursday, September 6 , 2012 at 8:30am EDT to Provide an Update on the Company's Business and Clinical Developments

NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (TGTX) today announced that it has initiated a Phase I/II trial to evaluate the safety, tolerability and efficacy of ublituximab, the company's novel third-generation anti-CD20 monoclonal antibody, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) who were previously treated with rituximab (Rituxan®). This is the company's first clinical trial conducted in North America and the first trial of ublituximab in patients with NHL. Previously, at the 53 rd Annual American Society of Hematology meeting in December 2011, Phase I data from a trial conducted in France of ublituximab administered as a single agent to patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) reported an objective response rate of 45%.

The trial, entitled "An Open Label Phase I/II Trial of the Efficacy and Safety of Ublituximab in Patients with B-cell Non-Hodgkin Lymphoma who have Relapsed or are Refractory After CD20 Directed Antibody Therapy," will enroll up to 36 patients in the Phase I dose escalation component.  Once the optimal dose is determined, up to 77 patients total will be enrolled for the Phase II component and stratified by subtype of B-cell Lymphoma, including Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Marginal Zone Lymphoma and other NHL subtypes.  All enrolled patients will be relapsed or refractory to Rituxan® or a Rituxan® containing regimen, and in most cases multiple other lines of therapy.  

"Ublituximab has demonstrated profound and sustained B-cell depletion in multiple pre-clinical NHL models, as well as impressive single agent activity in patients with relapsed/refractory CLL, and could now represent an important therapy for patients relapsed from or refractory to prior rituximab. We are excited to evaluate the role of ublituximab in this NHL patient population which is in great need of more effective therapies," stated Dr. Owen O'Connor, Professor of Medicine and Director, Center for Lymphoid Malignancies at New York Presbyterian Columbia Medical Center, and principle investigator of the trial.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,903.64 -139.26 -0.82%
S&P 500 1,961.42 -10.87 -0.55%
NASDAQ 4,454.5570 -38.8330 -0.86%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs